BCYC
Bicycle Therapeutics PLC
$
8.610
- Overview
- Forecast
- Valuation
- Earnings
High
8.900
Open
8.730
VWAP
--
Vol
152.44K
Mkt Cap
596.28M
Low
8.515
Amount
--
EV/EBITDA(TTM)
--
Total Shares
68.88M
EV
-189.49M
EV/OCF(TTM)
--
P/S(TTM)
21.93
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
9.43M
+0.73%
-0.934
+21.32%
8.71M
+225.43%
-1.005
+38.95%
8.55M
+130.61%
-0.933
+14.58%
Estimates Revision
The market is revising Upward the revenue expectations for Bicycle Therapeutics plc (BCYC) for FY2025, with the revenue forecasts being adjusted by 7.1% over the past three months. During the same period, the stock price has changed by 4.87%.
Revenue Estimates for FY2025
Revise Upward
+7.1%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+12.83%
In Past 3 Month
Stock Price
Go Up
+4.87%
In Past 3 Month
9 Analyst Rating
157.14% Upside
Wall Street analysts forecast BCYC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCYC is 22.14 USD with a low forecast of 14.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
2 Hold
0 Sell
Strong Buy
157.14% Upside
Current: 8.610
Low
14.00
Averages
22.14
High
33.00
157.14% Upside
Current: 8.610
Low
14.00
Averages
22.14
High
33.00
RBC Capital
Outperform
downgrade
$32 -> $25
2025-07-17
Reason
RBC Capital
Price Target
$32 -> $25
2025-07-17
downgrade
Outperform
Reason
RBC Capital lowered the firm's price target on Bicycle Therapeutics to $25 from $32 and keeps an Outperform rating on the shares. The firm is updating its views on Bicycle based on key opinion leader conversations and its updated model, noting that shares have been under pressure following what investors saw as an equivocal data set in an unforgiving environment, the analyst tells investors in a research note. Despite the caveats around cross-trial comparisons and early data sets, zelenectide may emerge as a differentiated therapeutic on tolerability vs. Padcev for mUC, the firm added.
Needham
Ami Fadia
Strong Buy
Reiterates
$30
2025-04-09
Reason
Needham
Ami Fadia
Price Target
$30
2025-04-09
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$30
2025-03-11
Reason
Needham
Ami Fadia
Price Target
$30
2025-03-11
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$30
2025-02-26
Reason
Needham
Ami Fadia
Price Target
$30
2025-02-26
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$33
2025-02-26
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$33
2025-02-26
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Reni Benjamin
Buy
Reiterates
$26
2025-02-26
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$26
2025-02-26
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bicycle Therapeutics PLC (BCYC.O) is -2.23, compared to its 5-year average forward P/E of -7.28. For a more detailed relative valuation and DCF analysis to assess Bicycle Therapeutics PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.28
Current PE
-2.23
Overvalued PE
-3.20
Undervalued PE
-11.36
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.82
Current EV/EBITDA
0.65
Overvalued EV/EBITDA
-0.38
Undervalued EV/EBITDA
-9.26
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
43.55
Current PS
16.73
Overvalued PS
68.01
Undervalued PS
19.09
Financials
Annual
Quarterly
FY2025Q1
YoY :
-48.91%
9.98M
Total Revenue
FY2025Q1
YoY :
+120.23%
-70.01M
Operating Profit
FY2025Q1
YoY :
+128.72%
-60.75M
Net Income after Tax
FY2025Q1
YoY :
+41.94%
-0.88
EPS - Diluted
FY2025Q1
YoY :
+22.70%
-86.97M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+347.72%
-608.94
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
77.1K
USD
11
3-6
Months
84.7K
USD
11
6-9
Months
705.3K
USD
16
0-12
Months
145.3K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
21.2M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
1.7M
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
2
1.0M
Volume
Months
6-9
1
543.1K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
77.1K
USD
11
3-6
Months
84.7K
USD
11
6-9
Months
705.3K
USD
16
0-12
Months
145.3K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
21.2M
USD
Months
0-12
0
0.0
USD
Months
BCYC News & Events
Events Timeline
2025-05-01 (ET)
2025-05-01
07:38:25
Bicycle Therapeutics reports Q1 EPS (88c), consensus (81c)
2025-03-27 (ET)
2025-03-27
07:18:04
Bicycle names Pierre Legault chairman, Eric Westin chief medical officer
2025-02-25 (ET)
2025-02-25
07:18:02
Bicycle Therapeutics reports Q4 EPS (75c), consensus (85c)
Sign Up For More Events
Sign Up For More Events
News
4.0
07-17BenzingaDemystifying Bicycle Therapeutics: Insights From 7 Analyst Reviews
5.0
07-02NewsfilterBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5.0
06-03NewsfilterBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sign Up For More News
People Also Watch
RUSHB
Rush Enterprises Inc
54.800
USD
-0.58%
ANGI
Angi Inc
16.700
USD
-1.53%
NCDL
Nuveen Churchill Direct Lending Corp
16.800
USD
-0.53%
ECVT
Ecovyst Inc
8.850
USD
-1.56%
CVAC
CureVac NV
5.420
USD
-0.73%
MSEX
Middlesex Water Co
51.520
USD
-1.11%
ACEL
Accel Entertainment Inc
12.820
USD
+0.63%
RDWR
Radware Ltd
27.980
USD
-1.86%
SLRC
SLR Investment Corp
16.240
USD
-0.79%
FAQ
What is Bicycle Therapeutics PLC (BCYC) stock price today?
The current price of BCYC is 8.61 USD — it has decreased -1.03 % in the last trading day.
What is Bicycle Therapeutics PLC (BCYC)'s business?
What is the price predicton of BCYC Stock?
What is Bicycle Therapeutics PLC (BCYC)'s revenue for the last quarter?
What is Bicycle Therapeutics PLC (BCYC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bicycle Therapeutics PLC (BCYC)'s fundamentals?
How many employees does Bicycle Therapeutics PLC (BCYC). have?